PMID- 33175614 OWN - NLM STAT- MEDLINE DCOM- 20210412 LR - 20210412 IS - 2164-554X (Electronic) IS - 2164-5515 (Print) IS - 2164-5515 (Linking) VI - 17 IP - 4 DP - 2021 Apr 3 TI - COVID-19 coronavirus vaccine T cell epitope prediction analysis based on distributions of HLA class I loci (HLA-A, -B, -C) across global populations. PG - 1097-1108 LID - 10.1080/21645515.2020.1823777 [doi] AB - T cell immunity, such as CD4 and/or CD8 T cell responses, plays a vital role in controlling the virus infection and pathological damage. Several studies have reported SARS-CoV-2 proteins could serve as ideal vaccine candidates against SARS-CoV-2 infection by activating the T cell responses. In the current study, based on the SARS-CoV-2 sequence and distribution of host human leukocyte antigen (HLA), we predicted the possible epitopes for the vaccine against SARS-CoV-2 infections. Firstly, the current study retrieved the SARS-CoV-2 S and N protein sequences from the NCBI Database. Then, using the Immune Epitope Database Analysis Resource, we predicted the CTL epitopes of the SARS-CoV-2 S and N proteins according to worldwide frequency distributions of HLA-A, -B, and -C alleles (>1%). Our results predicted 90 and 106 epitopes of N and S proteins, respectively. Epitope cluster analysis showed 16 and 34 respective clusters of SARS-CoV-2 N and S proteins, which covered 95.91% and 96.14% of the global population, respectively. After epitope conservancy analysis, 8 N protein epitopes and 6 S protein epitopes showed conservancy within two SARS-CoV-2 types. Of these 14 epitopes, 13 could cover SARS coronavirus and Bat SARS-like coronavirus. The remaining epitope (KWPWYIWLGF(1211-1220)) could cover MERS coronavirus. Finally, the 14-epitope combination could vaccinate 89.60% of all individuals worldwide. Our results propose single or combined CTL epitopes predicted in the current study as candidates for vaccines to effectively control SARS-CoV-2 infection and development. FAU - Cun, Yina AU - Cun Y AD - Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research & Development on Severe Infectious Diseases, Yunnan Engineering Research Centre of Vaccine Research & Development on Severe Infectious Diseases, Kunming, China. FAU - Li, Chuanyin AU - Li C AD - Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research & Development on Severe Infectious Diseases, Yunnan Engineering Research Centre of Vaccine Research & Development on Severe Infectious Diseases, Kunming, China. FAU - Shi, Lei AU - Shi L AD - Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research & Development on Severe Infectious Diseases, Yunnan Engineering Research Centre of Vaccine Research & Development on Severe Infectious Diseases, Kunming, China. FAU - Sun, Ming AU - Sun M AD - Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research & Development on Severe Infectious Diseases, Yunnan Engineering Research Centre of Vaccine Research & Development on Severe Infectious Diseases, Kunming, China. FAU - Dai, Shuying AU - Dai S AD - School of Basic Medical Science, Kunming Medical University, Kunming, China. FAU - Sun, Le AU - Sun L AD - School of Basic Medical Science, Kunming Medical University, Kunming, China. FAU - Shi, Li AU - Shi L AUID- ORCID: 0000-0001-9508-7863 AD - Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research & Development on Severe Infectious Diseases, Yunnan Engineering Research Centre of Vaccine Research & Development on Severe Infectious Diseases, Kunming, China. FAU - Yao, Yufeng AU - Yao Y AD - Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research & Development on Severe Infectious Diseases, Yunnan Engineering Research Centre of Vaccine Research & Development on Severe Infectious Diseases, Kunming, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20201111 PL - United States TA - Hum Vaccin Immunother JT - Human vaccines & immunotherapeutics JID - 101572652 RN - 0 (COVID-19 Vaccines) RN - 0 (Coronavirus Nucleocapsid Proteins) RN - 0 (Epitopes, B-Lymphocyte) RN - 0 (Epitopes, T-Lymphocyte) RN - 0 (HLA-A Antigens) RN - 0 (HLA-B Antigens) RN - 0 (HLA-C Antigens) RN - 0 (Phosphoproteins) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (nucleocapsid phosphoprotein, SARS-CoV-2) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - CD4-Positive T-Lymphocytes/immunology MH - CD8-Positive T-Lymphocytes/immunology MH - COVID-19/immunology/prevention & control MH - COVID-19 Vaccines/*immunology MH - Coronavirus Nucleocapsid Proteins/*immunology MH - Epitopes, B-Lymphocyte/immunology MH - Epitopes, T-Lymphocyte/*immunology MH - HLA-A Antigens/immunology MH - HLA-B Antigens/immunology MH - HLA-C Antigens/immunology MH - Humans MH - Immunogenicity, Vaccine/immunology MH - Phosphoproteins/immunology MH - SARS-CoV-2/*immunology MH - Spike Glycoprotein, Coronavirus/*immunology PMC - PMC7754929 OTO - NOTNLM OT - Human Leukocyte Antigen (HLA) OT - SARS-CoV-2 OT - T cell epitopes OT - population coverage OT - vaccine EDAT- 2020/11/12 06:00 MHDA- 2021/04/13 06:00 PMCR- 2020/11/11 CRDT- 2020/11/11 17:12 PHST- 2020/11/12 06:00 [pubmed] PHST- 2021/04/13 06:00 [medline] PHST- 2020/11/11 17:12 [entrez] PHST- 2020/11/11 00:00 [pmc-release] AID - 1823777 [pii] AID - 10.1080/21645515.2020.1823777 [doi] PST - ppublish SO - Hum Vaccin Immunother. 2021 Apr 3;17(4):1097-1108. doi: 10.1080/21645515.2020.1823777. Epub 2020 Nov 11.